|
Market Cap (11-Jun) $47,863,656 (0th) |
Close (30-Jun) $0.85 |
Volume (30-Jun) 942,590 |
Shortsold (27-Oct) 800,001 (0.58%) (257th) |
|
52w High $0.490 |
52w Low $0.312 |
P/E - |
EPS -0.06 |
IIQ released this announcement to the ASX on 17 January 2022, 8:48. The announcement is not marked as price sensitive, and is 1 page(s) in length and 129.15kb in size.
You can view all announcements from IIQ and see how they appear on a price chart on the announcements page.
At the date of this announcement, IIQ was 0.002% short sold according to ASIC data. It was ranked the 733rd most shorted stock on the ASX. It is now ranked as the 257th most shorted stock on the ASX with 0.576% of total shares short sold as of the latest reported data (27 October 2025).
| Other Recent Announcements from IIQ | |
|---|---|
| Notification of cessation of securities - IIQ | 30 June 2023, 14:19 |
| SubB2M/CA15.3 Clinical Validation Data Investor Presentation | 29 June 2023, 10:48 |
| INOVIQ Investor Briefing | 27 June 2023, 14:07 |
| US Patent Issued - BARD1 Breast & Ovarian Cancer Diagnosis | 17 January 2022, 8:48 |
| INOVIQ Awarded Additional BTB Funding to Develop SubB2M test | 10 January 2022, 8:59 |
| INOVIQ Appendix 4G and Corporate Governance Statement | 29 December 2021, 13:11 |
| Chinese Patent Issued in BARD1 Patent Family for Lung Cancer | 24 December 2021, 10:51 |
You must be logged in to post a reply.
